Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 45 articles:
HTML format
Text format



Single Articles


    October 2017
  1. IIJIMA Y, Hirotsu Y, Amemiya K, Ooka Y, et al
    Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
    Eur J Cancer. 2017;86:349-357.
    PubMed     Text format     Abstract available


  2. SORIA JC, Adjei AA, Bahleda R, Besse B, et al
    A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced n
    Eur J Cancer. 2017;86:186-196.
    PubMed     Text format     Abstract available


  3. DE LA PENA H, Sharma A, Glicksman C, Joseph J, et al
    No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer.
    Eur J Cancer. 2017;84:354-359.
    PubMed     Text format     Abstract available


    September 2017
  4. MAHJOUBI L, Gazzah A, Marabelle A, Le Roy Ladurie F, et al
    Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.
    Eur J Cancer. 2017 Sep 13. pii: S0959-8049(17)31197.
    PubMed     Text format    


  5. MCWILLIAM A, Kennedy J, Hodgson C, Vasquez Osorio E, et al
    Radiation dose to heart base linked with poorer survival in lung cancer patients.
    Eur J Cancer. 2017;85:106-113.
    PubMed     Text format     Abstract available


  6. LIN PL, Wu TC, Wu DW, Wang L, et al
    An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Eur J Cancer. 2017;85:95-105.
    PubMed     Text format     Abstract available


    August 2017
  7. LI F, Zhu T, Cao B, Wang J, et al
    Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Eur J Cancer. 2017;84:184-192.
    PubMed     Text format     Abstract available


  8. JIANG T, Ren S, Li X, Su C, et al
    The changing diagnostic pathway for lung cancer patients in Shanghai, China.
    Eur J Cancer. 2017;84:168-172.
    PubMed     Text format     Abstract available


  9. CUFARI ME, Proli C, De Sousa P, Raubenheimer H, et al
    Increasing frequency of non-smoking lung cancer: Presentation of patients with early disease to a tertiary institution in the UK.
    Eur J Cancer. 2017;84:55-59.
    PubMed     Text format     Abstract available


  10. FERRY D, Billingham L, Jarrett H, Dunlop D, et al
    Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.
    Eur J Cancer. 2017;83:302-312.
    PubMed     Text format     Abstract available


    July 2017
  11. SU C, Zhou F, Shen J, Zhao J, et al
    Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challen
    Eur J Cancer. 2017;83:266-278.
    PubMed     Text format     Abstract available


  12. SABRKHANY S, Kuijpers MJE, van Kuijk SMJ, Sanders L, et al
    A combination of platelet features allows detection of early-stage cancer.
    Eur J Cancer. 2017;80:5-13.
    PubMed     Text format     Abstract available


    June 2017
  13. GANDHI L, Ignatius Ou SH, Shaw AT, Barlesi F, et al
    Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
    Eur J Cancer. 2017;82:27-33.
    PubMed     Text format     Abstract available


  14. BERNABE R, Hickson N, Wallace A, Blackhall FH, et al
    What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?
    Eur J Cancer. 2017;81:66-73.
    PubMed     Text format     Abstract available


    May 2017
  15. BRIGHENTI M, Petrelli F, Barni S, Conti B, et al
    Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?
    Eur J Cancer. 2017;79:149-151.
    PubMed     Text format     Abstract available


  16. PASTORINO U, Morelli D, Leuzzi G, Gisabella M, et al
    Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer.
    Eur J Cancer. 2017;79:90-97.
    PubMed     Text format     Abstract available


  17. DE JONGE M, de Weger VA, Dickson MA, Langenberg M, et al
    A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
    Eur J Cancer. 2017;76:144-151.
    PubMed     Text format     Abstract available


  18. PALMERINI E, Chawla NS, Ferrari S, Sudan M, et al
    Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
    Eur J Cancer. 2017;76:118-124.
    PubMed     Text format     Abstract available


  19. RAVAUD A, de la Fouchardiere C, Caron P, Doussau A, et al
    A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
    Eur J Cancer. 2017;76:110-117.
    PubMed     Text format     Abstract available


  20. ZSCHABITZ S, Lasitschka F, Hadaschik B, Hofheinz RD, et al
    Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
    Eur J Cancer. 2017;76:1-7.
    PubMed     Text format     Abstract available


    April 2017
  21. GIROUX LEPRIEUR E, Dumenil C, Julie C, Giraud V, et al
    Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Eur J Cancer. 2017;78:16-23.
    PubMed     Text format     Abstract available


  22. SULLIVAN I, Le Teuff G, Guigay J, Caramella C, et al
    Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.
    Eur J Cancer. 2017;75:259-267.
    PubMed     Text format     Abstract available


  23. KIM S, Koh J, Kwon D, Keam B, et al
    Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas.
    Eur J Cancer. 2017;75:141-149.
    PubMed     Text format     Abstract available


    March 2017
  24. TWELVES C, Cortes J, O'Shaughnessy J, Awada A, et al
    Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
    Eur J Cancer. 2017;76:205-215.
    PubMed     Text format     Abstract available


  25. LEONE JP, Leone J, Zwenger AO, Iturbe J, et al
    Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
    Eur J Cancer. 2017;74:17-25.
    PubMed     Text format     Abstract available


    February 2017
  26. DE BAERE T, Tselikas L, Yevich S, Boige V, et al
    The role of image-guided therapy in the management of colorectal cancer metastatic disease.
    Eur J Cancer. 2017;75:231-242.
    PubMed     Text format     Abstract available


  27. WALDER D, O'Brien M
    Looking back and to the future: Are we improving 'cure' in non-small cell lung cancer?
    Eur J Cancer. 2017;75:192-194.
    PubMed     Text format     Abstract available


  28. SCHAFFAR R, Rachet B, Belot A, Woods LM, et al
    Estimation of net survival for cancer patients: Relative survival setting more robust to some assumption violations than cause-specific setting, a sensitivity analysis on empirical data.
    Eur J Cancer. 2017;72:78-83.
    PubMed     Text format     Abstract available


    December 2016
  29. GEERSE OP, Hoekstra-Weebers JE, Stokroos MH, Burgerhof JG, et al
    Structural distress screening and supportive care for patients with lung cancer on systemic therapy: A randomised controlled trial.
    Eur J Cancer. 2016;72:37-45.
    PubMed     Text format     Abstract available


    November 2016
  30. YAP TA, Macklin-Doherty A, Popat S
    Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer.
    Eur J Cancer. 2016;70:12-21.
    PubMed     Text format     Abstract available


    June 2016
  31. MOLLER H, Riaz SP, Holmberg L, Jakobsen E, et al
    High lung cancer surgical procedure volume is associated with shorter length of stay and lower risks of re-admission and death: National cohort analysis in England.
    Eur J Cancer. 2016;64:32-43.
    PubMed     Text format     Abstract available


    May 2016
  32. COUREAU G, Salmi LR, Etard C, Sancho-Garnier H, et al
    Low-dose computed tomography screening for lung cancer in populations highly exposed to tobacco: A systematic methodological appraisal of published randomised controlled trials.
    Eur J Cancer. 2016 May 15. pii: S0959-8049(16)32064.
    PubMed     Text format     Abstract available


  33. MINCHOM A, Punwani R, Filshie J, Bhosle J, et al
    A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma.
    Eur J Cancer. 2016;61:102-110.
    PubMed     Text format     Abstract available


    April 2016
  34. SHARP A, Bhosle J, Abdelraouf F, Popat S, et al
    Development of molecularly targeted agents and immunotherapies in small cell lung cancer.
    Eur J Cancer. 2016;60:26-39.
    PubMed     Text format     Abstract available


  35. YANG CY, Lin MW, Chang YL, Wu CT, et al
    Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Eur J Cancer. 2016;57:91-103.
    PubMed     Text format     Abstract available


    March 2016
  36. WELLER A, O'Brien ME, Ahmed M, Popat S, et al
    Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer.
    Eur J Cancer. 2016;59:65-78.
    PubMed     Text format     Abstract available


  37. STEFFENS M, Paul T, Hichert V, Scholl C, et al
    Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Eur J Cancer. 2016;55:131-9.
    PubMed     Text format     Abstract available


    February 2016
  38. KARAYAMA M, Inui N, Fujisawa T, Enomoto N, et al
    Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
    Eur J Cancer. 2016;58:30-37.
    PubMed     Text format     Abstract available


  39. VILLARUZ LC, Socinski MA
    Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes.
    Eur J Cancer. 2016;56:162-171.
    PubMed     Text format     Abstract available


    January 2016
  40. TOKITO T, Azuma K, Kawahara A, Ishii H, et al
    Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Eur J Cancer. 2016;55:7-14.
    PubMed     Text format     Abstract available


    December 2015
  41. ABDELRAOUF F, Smit E, Hasan B, Menis J, et al
    Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).
    Eur J Cancer. 2015;54:35-39.
    PubMed     Text format     Abstract available


  42. FOURNEL P, Vergnenegre A, Robinet G, Lena H, et al
    Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
    Eur J Cancer. 2015;52:181-187.
    PubMed     Text format     Abstract available


  43. FITENI F, Vernerey D, Bonnetain F, Vaylet F, et al
    Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.
    Eur J Cancer. 2015;52:120-128.
    PubMed     Text format     Abstract available


    November 2015
  44. ROSSI M, Carioli G, Bonifazi M, Zambelli A, et al
    Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
    Eur J Cancer. 2015;52:41-49.
    PubMed     Text format     Abstract available


    July 2015
  45. PREUSSER M, Berghoff AS, Koller R, Zielinski CC, et al
    Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.
    Eur J Cancer. 2015 Jul 8. pii: S0959-8049(15)00622.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: